PMC:7060195 / 446-9466
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
30 | 15-37 | Species | denotes | 2019-novel coronavirus | Tax:2697049 |
31 | 39-49 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
32 | 475-481 | Species | denotes | people | Tax:9606 |
33 | 531-536 | Species | denotes | human | Tax:9606 |
34 | 540-545 | Species | denotes | human | Tax:9606 |
35 | 794-804 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
36 | 940-948 | Species | denotes | patients | Tax:9606 |
37 | 1149-1159 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
38 | 72-81 | Disease | denotes | pneumonia | MESH:D011014 |
39 | 83-91 | Disease | denotes | COVID-19 | MESH:C000657245 |
40 | 391-412 | Disease | denotes | SARS-CoV-2 infections | MESH:C000657245 |
41 | 487-491 | Disease | denotes | died | MESH:D003643 |
42 | 503-511 | Disease | denotes | COVID-19 | MESH:C000657245 |
43 | 669-678 | Disease | denotes | pneumonia | MESH:D011014 |
44 | 862-867 | Disease | denotes | Fever | MESH:D005334 |
45 | 869-878 | Disease | denotes | dry cough | MESH:D003371 |
46 | 884-891 | Disease | denotes | fatigue | MESH:D005221 |
47 | 924-932 | Disease | denotes | COVID-19 | MESH:C000657245 |
48 | 954-965 | Disease | denotes | lymphopenia | MESH:D008231 |
49 | 1119-1132 | Disease | denotes | viral disease | MESH:D001102 |
52 | 3238-3244 | Species | denotes | humans | Tax:9606 |
53 | 3271-3279 | Disease | denotes | toxicity | MESH:D064420 |
64 | 1454-1458 | Gene | denotes | Hu-1 | Gene:3215 |
65 | 1436-1446 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
66 | 1617-1627 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
67 | 1933-1943 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
68 | 2336-2346 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
69 | 1405-1414 | Species | denotes | influenza | Tax:11320 |
70 | 1788-1800 | Chemical | denotes | formaldehyde | MESH:D005557 |
71 | 1806-1821 | Chemical | denotes | β-propiolactone | MESH:D011420 |
72 | 1994-2005 | Disease | denotes | lung injury | MESH:D055370 |
73 | 1567-1577 | CellLine | denotes | MN908947.3 | CVCL:U508 |
99 | 4101-4102 | Gene | denotes | E | Gene:43740570 |
100 | 4105-4113 | Gene | denotes | membrane | Gene:43740571 |
101 | 4115-4116 | Gene | denotes | M | Gene:43740571 |
102 | 4133-4134 | Gene | denotes | N | Gene:43740575 |
103 | 4141-4146 | Gene | denotes | spike | Gene:43740568 |
104 | 4148-4149 | Gene | denotes | S | Gene:43740568 |
105 | 4245-4248 | Gene | denotes | CD4 | Gene:920 |
106 | 4250-4253 | Gene | denotes | CD8 | Gene:925 |
107 | 4119-4131 | Gene | denotes | nucleocapsid | Gene:43740575 |
108 | 3449-3459 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
109 | 3698-3708 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
110 | 3730-3738 | Species | denotes | SARS-CoV | Tax:694009 |
111 | 3743-3798 | Species | denotes | Middle East respiratory syndrome coronavirus (MERS-CoV) | Tax:1335626 |
112 | 4042-4052 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
113 | 4402-4411 | Disease | denotes | hepatitis | MESH:D056486 |
114 | 3502-3512 | CellLine | denotes | MN908947.3 | CVCL:U508 |
115 | 3514-3524 | CellLine | denotes | MN975262.1 | CVCL:U508 |
116 | 3539-3549 | CellLine | denotes | MN997409.1 | CVCL:U508 |
117 | 3551-3561 | CellLine | denotes | MN985325.1 | CVCL:U508 |
118 | 3563-3573 | CellLine | denotes | MN988669.1 | CVCL:U508 |
119 | 3575-3585 | CellLine | denotes | MN988668.1 | CVCL:U508 |
120 | 3587-3597 | CellLine | denotes | MN994468.1 | CVCL:U508 |
121 | 3599-3609 | CellLine | denotes | MN994467.1 | CVCL:U508 |
122 | 3611-3621 | CellLine | denotes | MN988713.1 | CVCL:U508 |
123 | 3627-3637 | CellLine | denotes | MN938384.1 | CVCL:U508 |
152 | 6285-6316 | Gene | denotes | angiotensin-converting enzyme 2 | Gene:59272 |
153 | 6318-6322 | Gene | denotes | ACE2 | Gene:59272 |
154 | 5606-5607 | Gene | denotes | S | Gene:43740568 |
155 | 5540-5541 | Gene | denotes | S | Gene:43740568 |
156 | 4925-4936 | Species | denotes | coronavirus | Tax:11118 |
157 | 5045-5049 | Species | denotes | CoVs | Tax:11118 |
158 | 5114-5122 | Species | denotes | SARS-CoV | Tax:694009 |
159 | 5126-5134 | Species | denotes | MERS-CoV | Tax:1335626 |
160 | 5281-5289 | Species | denotes | SARS-CoV | Tax:694009 |
161 | 5333-5336 | Species | denotes | CoV | Tax:11118 |
162 | 5459-5469 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
163 | 5545-5555 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
164 | 5629-5639 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
165 | 5755-5765 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
166 | 5815-5824 | Species | denotes | SARS-CoVs | Tax:694009 |
167 | 6124-6141 | Species | denotes | influenza A virus | Tax:11320 |
168 | 6354-6363 | Species | denotes | 2019-nCoV | Tax:2697049 |
169 | 6403-6408 | Species | denotes | human | Tax:9606 |
170 | 6409-6418 | Species | denotes | SARS-CoVs | Tax:694009 |
171 | 6891-6900 | Species | denotes | SARS-CoVs | Tax:694009 |
172 | 6950-6971 | Species | denotes | African green monkeys | Tax:9534 |
173 | 7006-7014 | Species | denotes | SARS-CoV | Tax:694009 |
174 | 7059-7067 | Species | denotes | SARS-CoV | Tax:694009 |
175 | 7097-7105 | Species | denotes | SARS-CoV | Tax:694009 |
176 | 7290-7300 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
177 | 6004-6013 | Species | denotes | influenza | Tax:11320 |
178 | 5501-5510 | Disease | denotes | infection | MESH:D007239 |
179 | 6693-6708 | Disease | denotes | viral infection | MESH:D001102 |
184 | 7987-7995 | Gene | denotes | membrane | Gene:43740571 |
185 | 7644-7654 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
186 | 7786-7796 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
187 | 7577-7604 | Disease | denotes | respiratory tract infection | MESH:D012141 |
193 | 8314-8316 | Gene | denotes | S1 | |
194 | 8519-8522 | Gene | denotes | GSK | |
195 | 8351-8361 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
196 | 8927-8937 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
197 | 8178-8186 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 1012-1017 | Body_part | denotes | chest | http://purl.org/sig/ont/fma/fma9576 |
T2 | 1994-1998 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T3 | 2026-2036 | Body_part | denotes | neutrophil | http://purl.org/sig/ont/fma/fma62860 |
T4 | 2077-2085 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
T5 | 3133-3136 | Body_part | denotes | DNA | http://purl.org/sig/ont/fma/fma74412 |
T6 | 3283-3287 | Body_part | denotes | mRNA | http://purl.org/sig/ont/fma/fma67122 |
T7 | 3460-3467 | Body_part | denotes | genomes | http://purl.org/sig/ont/fma/fma84116 |
T8 | 3847-3850 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T9 | 3864-3870 | Body_part | denotes | genome | http://purl.org/sig/ont/fma/fma84116 |
T10 | 3889-3900 | Body_part | denotes | nucleotides | http://purl.org/sig/ont/fma/fma82740 |
T11 | 4073-4081 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
T12 | 4164-4172 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
T13 | 4257-4261 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T14 | 4516-4519 | Body_part | denotes | DNA | http://purl.org/sig/ont/fma/fma74412 |
T15 | 4524-4528 | Body_part | denotes | mRNA | http://purl.org/sig/ont/fma/fma67122 |
T16 | 4864-4872 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
T17 | 4948-4955 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T18 | 4979-4982 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T19 | 5010-5017 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T20 | 5152-5159 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T21 | 5200-5207 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T22 | 5253-5260 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T23 | 5261-5264 | Body_part | denotes | DNA | http://purl.org/sig/ont/fma/fma74412 |
T24 | 5318-5325 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T25 | 5448-5455 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T26 | 5527-5539 | Body_part | denotes | glycoprotein | http://purl.org/sig/ont/fma/fma62925 |
T27 | 5618-5625 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T28 | 5723-5730 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T29 | 5863-5870 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T30 | 5956-5966 | Body_part | denotes | Antibodies | http://purl.org/sig/ont/fma/fma62871 |
T31 | 6262-6267 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
T32 | 6343-6350 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T33 | 6456-6467 | Body_part | denotes | amino acids | http://purl.org/sig/ont/fma/fma82739 |
T34 | 6782-6789 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T35 | 6818-6826 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T36 | 6995-7002 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T37 | 7110-7118 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
T38 | 7577-7594 | Body_part | denotes | respiratory tract | http://purl.org/sig/ont/fma/fma265130 |
T39 | 7826-7829 | Body_part | denotes | DNA | http://purl.org/sig/ont/fma/fma74412 |
T40 | 7856-7859 | Body_part | denotes | DNA | http://purl.org/sig/ont/fma/fma74412 |
T41 | 8317-8324 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T42 | 8957-8961 | Body_part | denotes | gene | http://purl.org/sig/ont/fma/fma74402 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 1012-1017 | Body_part | denotes | chest | http://purl.obolibrary.org/obo/UBERON_0001443 |
T2 | 1600-1605 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T3 | 1994-1998 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
T4 | 7577-7594 | Body_part | denotes | respiratory tract | http://purl.obolibrary.org/obo/UBERON_0000065 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T2 | 72-81 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T3 | 669-678 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T4 | 862-867 | Phenotype | denotes | Fever | http://purl.obolibrary.org/obo/HP_0001945 |
T5 | 869-878 | Phenotype | denotes | dry cough | http://purl.obolibrary.org/obo/HP_0031246 |
T6 | 884-891 | Phenotype | denotes | fatigue | http://purl.obolibrary.org/obo/HP_0012378 |
T7 | 954-965 | Phenotype | denotes | lymphopenia | http://purl.obolibrary.org/obo/HP_0001888 |
T8 | 4402-4411 | Phenotype | denotes | hepatitis | http://purl.obolibrary.org/obo/HP_0012115 |
T9 | 7577-7604 | Phenotype | denotes | respiratory tract infection | http://purl.obolibrary.org/obo/HP_0011947 |
LitCovid_AGAC
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
p10944s31 | 2007-2017 | NegReg | denotes | diminished |
p10944s33 | 2026-2043 | CPA | denotes | neutrophil influx |
p10944s41 | 2077-2097 | MPA | denotes | cytokine expressions |
p10963s4 | 5018-5027 | NegReg | denotes | abrogated |
p10963s6 | 5032-5041 | MPA | denotes | virulence |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T6 | 39-47 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T7 | 72-81 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
T8 | 83-91 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T9 | 391-399 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T10 | 402-412 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
T11 | 503-511 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T12 | 669-678 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
T13 | 794-802 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T14 | 954-965 | Disease | denotes | lymphopenia | http://purl.obolibrary.org/obo/MONDO_0003783 |
T15 | 1119-1132 | Disease | denotes | viral disease | http://purl.obolibrary.org/obo/MONDO_0005108 |
T16 | 1149-1157 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T17 | 1405-1414 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
T18 | 1436-1444 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T19 | 1617-1625 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T20 | 1933-1941 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T21 | 1999-2005 | Disease | denotes | injury | http://purl.obolibrary.org/obo/MONDO_0021178 |
T22 | 2336-2344 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T23 | 3449-3457 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T24 | 3698-3706 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T25 | 3730-3738 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T26 | 4042-4050 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T27 | 4402-4413 | Disease | denotes | hepatitis B | http://purl.obolibrary.org/obo/MONDO_0005344 |
T28 | 4402-4411 | Disease | denotes | hepatitis | http://purl.obolibrary.org/obo/MONDO_0002251 |
T29 | 5114-5122 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T30 | 5281-5289 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T31 | 5459-5467 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T32 | 5545-5553 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T33 | 5629-5637 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T34 | 5755-5763 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T35 | 5815-5819 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T36 | 6004-6013 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
T37 | 6124-6133 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
T38 | 6409-6413 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T39 | 6693-6708 | Disease | denotes | viral infection | http://purl.obolibrary.org/obo/MONDO_0005108 |
T40 | 6699-6708 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T41 | 6719-6723 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T42 | 6891-6895 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T43 | 7006-7014 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T44 | 7059-7067 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T45 | 7097-7105 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T46 | 7290-7298 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T47 | 7577-7604 | Disease | denotes | respiratory tract infection | http://purl.obolibrary.org/obo/MONDO_0024355 |
T48 | 7595-7604 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T49 | 7644-7652 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T50 | 7786-7794 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T51 | 8178-8186 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T52 | 8351-8359 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T53 | 8927-8935 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T4 | 93-96 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T5 | 140-143 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T6 | 362-363 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T7 | 528-536 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | by human |
T8 | 540-545 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T9 | 564-565 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T10 | 853-854 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T11 | 1012-1017 | http://www.ebi.ac.uk/efo/EFO_0000965 | denotes | chest |
T12 | 1104-1105 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T13 | 1208-1213 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T14 | 1291-1296 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T15 | 1670-1675 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T16 | 1854-1859 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T17 | 1994-1998 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T18 | 1994-1998 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T19 | 2166-2171 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T20 | 2314-2322 | http://purl.obolibrary.org/obo/PR_000018263 | denotes | peptides |
T21 | 2504-2509 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T22 | 2657-2662 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T23 | 3238-3244 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | humans |
T24 | 3668-3673 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T25 | 3851-3856 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T26 | 3862-3863 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T27 | 4033-4034 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T28 | 4053-4056 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T29 | 4105-4113 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membrane |
T30 | 4245-4248 | http://purl.obolibrary.org/obo/PR_000001004 | denotes | CD4 |
T31 | 4250-4253 | http://purl.obolibrary.org/obo/CLO_0053438 | denotes | CD8 |
T32 | 4255-4261 | http://purl.obolibrary.org/obo/CL_0000084 | denotes | T-cell |
T33 | 4412-4413 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | B |
T34 | 4491-4497 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
T35 | 4923-4924 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T36 | 5140-5141 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T37 | 5369-5370 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T38 | 5575-5580 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T39 | 5676-5678 | http://purl.obolibrary.org/obo/CLO_0050050 | denotes | S1 |
T40 | 5684-5686 | http://purl.obolibrary.org/obo/CLO_0001627 | denotes | aa |
T41 | 5692-5694 | http://purl.obolibrary.org/obo/CLO_0008922 | denotes | S2 |
T42 | 5692-5694 | http://purl.obolibrary.org/obo/CLO_0050052 | denotes | S2 |
T43 | 5700-5702 | http://purl.obolibrary.org/obo/CLO_0001627 | denotes | aa |
T44 | 5720-5722 | http://purl.obolibrary.org/obo/CLO_0008922 | denotes | S2 |
T45 | 5720-5722 | http://purl.obolibrary.org/obo/CLO_0050052 | denotes | S2 |
T46 | 5766-5773 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | viruses |
T47 | 5811-5814 | http://purl.obolibrary.org/obo/NCBITaxon_9397 | denotes | bat |
T48 | 5860-5862 | http://purl.obolibrary.org/obo/CLO_0008922 | denotes | S2 |
T49 | 5860-5862 | http://purl.obolibrary.org/obo/CLO_0050052 | denotes | S2 |
T50 | 5930-5937 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
T51 | 5941-5947 | http://purl.obolibrary.org/obo/NCBITaxon_33208 | denotes | animal |
T52 | 6134-6135 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T53 | 6162-6164 | http://purl.obolibrary.org/obo/CLO_0050050 | denotes | S1 |
T54 | 6235-6240 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T55 | 6262-6267 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
T56 | 6340-6342 | http://purl.obolibrary.org/obo/CLO_0050050 | denotes | S1 |
T57 | 6403-6408 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T58 | 6573-6578 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T59 | 6633-6634 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T60 | 6635-6640 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T61 | 6656-6657 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T62 | 6852-6853 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T63 | 6964-6971 | http://purl.obolibrary.org/obo/NCBITaxon_9479 | denotes | monkeys |
T64 | 7024-7031 | http://purl.obolibrary.org/obo/NCBITaxon_9479 | denotes | monkeys |
T65 | 7210-7216 | http://purl.obolibrary.org/obo/NCBITaxon_33208 | denotes | animal |
T66 | 7276-7278 | http://purl.obolibrary.org/obo/CLO_0050050 | denotes | S1 |
T67 | 7369-7375 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
T68 | 7566-7567 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T69 | 7819-7820 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T70 | 7886-7891 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T71 | 7960-7968 | http://purl.obolibrary.org/obo/NCBITaxon_2 | denotes | bacteria |
T72 | 7987-7995 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membrane |
T73 | 8121-8126 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T74 | 8214-8219 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T75 | 8314-8316 | http://purl.obolibrary.org/obo/CLO_0050050 | denotes | S1 |
T76 | 8560-8561 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T77 | 8705-8706 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T78 | 8921-8922 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T79 | 8957-8961 | http://purl.obolibrary.org/obo/OGG_0000000002 | denotes | gene |
T80 | 8983-8990 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T3 | 1043-1052 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T4 | 1788-1800 | Chemical | denotes | formaldehyde | http://purl.obolibrary.org/obo/CHEBI_16842 |
T5 | 2306-2313 | Chemical | denotes | antigen | http://purl.obolibrary.org/obo/CHEBI_59132 |
T6 | 2314-2322 | Chemical | denotes | peptides | http://purl.obolibrary.org/obo/CHEBI_16670 |
T7 | 2994-3003 | Chemical | denotes | adjuvants | http://purl.obolibrary.org/obo/CHEBI_60809 |
T8 | 3133-3136 | Chemical | denotes | DNA | http://purl.obolibrary.org/obo/CHEBI_16991 |
T9 | 3889-3900 | Chemical | denotes | nucleotides | http://purl.obolibrary.org/obo/CHEBI_36976 |
T10 | 4073-4081 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
T11 | 4164-4172 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
T12 | 4186-4194 | Chemical | denotes | antigens | http://purl.obolibrary.org/obo/CHEBI_59132 |
T13 | 4346-4355 | Chemical | denotes | adjuvants | http://purl.obolibrary.org/obo/CHEBI_60809 |
T14 | 4422-4429 | Chemical | denotes | antigen | http://purl.obolibrary.org/obo/CHEBI_59132 |
T15 | 4516-4519 | Chemical | denotes | DNA | http://purl.obolibrary.org/obo/CHEBI_16991 |
T16 | 4789-4797 | Chemical | denotes | antigens | http://purl.obolibrary.org/obo/CHEBI_59132 |
T17 | 4864-4872 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
T18 | 4948-4955 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T19 | 5010-5017 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T20 | 5152-5159 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T21 | 5200-5207 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T22 | 5253-5260 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T23 | 5261-5264 | Chemical | denotes | DNA | http://purl.obolibrary.org/obo/CHEBI_16991 |
T24 | 5318-5325 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T25 | 5448-5455 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T26 | 5527-5539 | Chemical | denotes | glycoprotein | http://purl.obolibrary.org/obo/CHEBI_17089 |
T27 | 5618-5625 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T28 | 5692-5694 | Chemical | denotes | S2 | http://purl.obolibrary.org/obo/CHEBI_29387 |
T29 | 5720-5722 | Chemical | denotes | S2 | http://purl.obolibrary.org/obo/CHEBI_29387 |
T30 | 5723-5730 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T31 | 5860-5862 | Chemical | denotes | S2 | http://purl.obolibrary.org/obo/CHEBI_29387 |
T32 | 5863-5870 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T33 | 5900-5909 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T34 | 6285-6296 | Chemical | denotes | angiotensin | http://purl.obolibrary.org/obo/CHEBI_48433 |
T35 | 6343-6350 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T36 | 6456-6467 | Chemical | denotes | amino acids | http://purl.obolibrary.org/obo/CHEBI_33709 |
T37 | 6456-6461 | Chemical | denotes | amino | http://purl.obolibrary.org/obo/CHEBI_46882 |
T38 | 6462-6467 | Chemical | denotes | acids | http://purl.obolibrary.org/obo/CHEBI_37527 |
T39 | 6782-6789 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T40 | 6995-7002 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T41 | 7110-7118 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
T42 | 7543-7552 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T43 | 7826-7829 | Chemical | denotes | DNA | http://purl.obolibrary.org/obo/CHEBI_16991 |
T44 | 7856-7859 | Chemical | denotes | DNA | http://purl.obolibrary.org/obo/CHEBI_16991 |
T45 | 8317-8324 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T46 | 8460-8469 | Chemical | denotes | adjuvants | http://purl.obolibrary.org/obo/CHEBI_60809 |
T47 | 8478-8482 | Chemical | denotes | alum | http://purl.obolibrary.org/obo/CHEBI_74768 |
T48 | 8497-8506 | Chemical | denotes | adjuvants | http://purl.obolibrary.org/obo/CHEBI_60809 |
T49 | 8536-8545 | Chemical | denotes | adjuvants | http://purl.obolibrary.org/obo/CHEBI_60809 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 1957-1969 | http://purl.obolibrary.org/obo/GO_0009405 | denotes | pathogenesis |
T2 | 2703-2719 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune responses |
T3 | 2873-2897 | http://purl.obolibrary.org/obo/GO_0006959 | denotes | humoral immune responses |
T4 | 3066-3090 | http://purl.obolibrary.org/obo/GO_0006959 | denotes | humoral immune responses |
T5 | 3218-3234 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune responses |
T6 | 3358-3374 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune responses |
T7 | 3971-3980 | http://purl.obolibrary.org/obo/GO_0009058 | denotes | synthesis |
T8 | 4905-4919 | http://purl.obolibrary.org/obo/GO_0019068 | denotes | viral assembly |
T9 | 5032-5041 | http://purl.obolibrary.org/obo/GO_0016032 | denotes | virulence |
T10 | 5032-5041 | http://purl.obolibrary.org/obo/GO_0009405 | denotes | virulence |
T11 | 5224-5239 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
T12 | 6693-6708 | http://purl.obolibrary.org/obo/GO_0016032 | denotes | viral infection |
T13 | 7735-7759 | http://purl.obolibrary.org/obo/GO_0002385 | denotes | mucosal immune responses |
T14 | 8821-8837 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune responses |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T5 | 0-187 | Sentence | denotes | An outbreak of 2019-novel coronavirus (SARS-CoV-2) that causes atypical pneumonia (COVID-19) has raged in China since mid-December 2019 and has spread to 26 countries (February 20, 2020). |
T6 | 188-361 | Sentence | denotes | The epidemic was identified by the first four cases confirmed on December 29, 2019 and was traced to the Huanan Seafood Wholesale Market, Wuhan city, Hubei Province, China1. |
T7 | 362-502 | Sentence | denotes | A total of 75,465 cases with SARS-CoV-2 infections have been confirmed up to date (February 20, 2020), and 2,236 people have died in China2. |
T8 | 503-712 | Sentence | denotes | COVID-19 spreads rapidly by human-to-human transmission with a median incubation period of 3.0 days (range, 0 to 24.0), and the time from symptom onset to developing pneumonia is 4.0 days (range, 2.0 to 7.0)3. |
T9 | 713-861 | Sentence | denotes | Respiratory droplets and direct contact are conventional transmission routes for SARS-CoV-2, and fecal-to-oral transmission might also have a role3. |
T10 | 862-934 | Sentence | denotes | Fever, dry cough, and fatigue are common symptoms at onset of COVID-194. |
T11 | 935-1030 | Sentence | denotes | Most patients have lymphopenia and bilateral ground-glass opacity changes on chest CT scans4,5. |
T12 | 1031-1133 | Sentence | denotes | No specific antiviral treatments or vaccines are available because it is a new emerging viral disease. |
T13 | 1134-1196 | Sentence | denotes | Development of SARS-CoV-2-based vaccines is urgently required. |
T14 | 1197-1425 | Sentence | denotes | The entire virus particle-based preparation of vaccines, including inactivated and attenuated virus vaccines is advisable, because it is based on previous studies about the prevention and control of seasonal influenza vaccines6. |
T15 | 1426-1566 | Sentence | denotes | The first SARS-CoV-2 (Wuhan-Hu-1) was successfully sequenced and its genomic sequence submitted to GenBank on January 5, 2020 (Accession no. |
T16 | 1567-1580 | Sentence | denotes | MN908947.3)7. |
T17 | 1581-1823 | Sentence | denotes | Subsequently large-scale culture of SARS-CoV-2 was quickly performed, and an inactivated virus vaccine could be prepared through the employment of established physical and chemical methods such as UV light, formaldehyde, and β-propiolactone8. |
T18 | 1824-2133 | Sentence | denotes | The development of attenuated-virus vaccines is also possible by carefully screening the serially propagated SARS-CoV-2 with reduced pathogenesis such as induced minimal lung injury, diminished limited neutrophil influx, and increased anti-inflammatory cytokine expressions compared with the wild-type virus9. |
T19 | 2134-2237 | Sentence | denotes | Both inactivated and attenuated virus vaccines have their own disadvantages and side effects (Table 1). |
T20 | 2238-2368 | Sentence | denotes | Alternatively, new vaccine designs based on the putative protective antigen/peptides derived from SARS-CoV-2 should be considered. |
T21 | 2369-2438 | Sentence | denotes | Table 1 Advantages and disadvantages of different vaccine strategies. |
T22 | 2439-2491 | Sentence | denotes | Vaccine strategy Advantages Disadvantages References |
T23 | 2492-2645 | Sentence | denotes | Inactivated virus vaccines Easy to prepare; safety; high-titer neutralizing antibodies Potential inappropriate for highly immunosuppressed individuals 25 |
T24 | 2646-2795 | Sentence | denotes | Attenuated virus vaccines Rapid development; induce high immune responses Phenotypic or genotypic reversion possible; can still cause some disease 25 |
T25 | 2796-3009 | Sentence | denotes | Subunit vaccines High safety; consistent production; can induce cellular and humoral immune responses; high-titer neutralizing antibodies High cost; lower immunogenicity; require repeated doses and adjuvants 12,14 |
T26 | 3010-3132 | Sentence | denotes | Viral vector vaccines Safety; induces high cellular and humoral immune responses Possibly present pre-existing immunity 12 |
T27 | 3133-3282 | Sentence | denotes | DNA vaccines Easier to design; high safety; high-titer neutralizing antibodies Lower immune responses in humans; repeated doses may cause toxicity 23 |
T28 | 3283-3424 | Sentence | denotes | mRNA vaccines Easier to design; high degree of adaptability; induce strong immune responses Highly unstable under physiological conditions 23 |
T29 | 3425-3697 | Sentence | denotes | Accumulated releases of SARS-CoV-2 genomes such as GenBank accession numbers MN908947.3, MN975262.1, NC_045512.2, MN997409.1, MN985325.1, MN988669.1, MN988668.1, MN994468.1, MN994467.1, MN988713.1, and MN938384.1 facilitate the development of virus-based subunit vaccines. |
T30 | 3698-4032 | Sentence | denotes | SARS-CoV-2, which is similar to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), is an enveloped, single- and positive-stranded RNA virus with a genome comprising 29,891 nucleotides, which encode the 12 putative open reading frames responsible for the synthesis of viral structural and nonstructural proteins7,10. |
T31 | 4033-4153 | Sentence | denotes | A mature SARS-CoV-2 has four structural proteins, namely, envelope (E), membrane (M), nucleocapsid (N), and spike (S)10. |
T32 | 4154-4275 | Sentence | denotes | All these proteins may serve as antigens to stimulate neutralizing antibodies and increase CD4+/CD8+ T-cell responses8,9. |
T33 | 4276-4511 | Sentence | denotes | However, subunit vaccines require multiple booster shots and suitable adjuvants to work, and certain subunit vaccines such as hepatitis B surface antigen, PreS1, and PreS2 may fail to yield protective response when tested clinically11. |
T34 | 4512-4630 | Sentence | denotes | The DNA and mRNA vaccines that are easier to design and proceed into clinical trials very quickly remain experimental. |
T35 | 4631-4728 | Sentence | denotes | The viral vector-based vaccines could also be quickly constructed and used without an adjuvant12. |
T36 | 4729-4851 | Sentence | denotes | However, development of such vaccines might not start until antigens containing the neutralizing epitopes are identified8. |
T37 | 4852-4995 | Sentence | denotes | The E and M proteins have important functions in the viral assembly of a coronavirus, and the N protein is necessary for viral RNA synthesis13. |
T38 | 4996-5193 | Sentence | denotes | Deletion of E protein abrogated the virulence of CoVs, and several studies have explored the potential of recombinant SARS-CoV or MERS-CoV with a mutated E protein as live attenuated vaccines13,14. |
T39 | 5194-5513 | Sentence | denotes | The M protein can augment the immune response induced by N protein DNA vaccine against SARS-CoV;15 however, the conserved N protein across CoV families implies that it is not a suitable candidate for vaccine development, and the antibodies against the N protein of SARS-CoV-2 do not provide immunity to the infection16. |
T40 | 5514-5601 | Sentence | denotes | The critical glycoprotein S of SARS-CoV-2 is responsible for virus binding and entry16. |
T41 | 5602-5715 | Sentence | denotes | The S precursor protein of SARS-CoV-2 can be proteolytically cleaved into S1 (685 aa) and S2 (588 aa) subunits10. |
T42 | 5716-5827 | Sentence | denotes | The S2 protein is well conserved among SARS-CoV-2 viruses and shares 99% identity with that of bat SARS-CoVs10. |
T43 | 5828-5955 | Sentence | denotes | The vaccine design based on the S2 protein may boost the broad-spectrum antiviral effect and is worth testing in animal models. |
T44 | 5956-6144 | Sentence | denotes | Antibodies against the conserved stem region of influenza hemagglutinin have been found to exhibit broadly cross-reactive immunity, but are less potent in neutralizing influenza A virus17. |
T45 | 6145-6335 | Sentence | denotes | In contrast, the S1 subunit consists of the receptor-binding domain (RBD), which mediates virus entry into sensitive cells through the host angiotensin-converting enzyme 2 (ACE2) receptor18. |
T46 | 6336-6419 | Sentence | denotes | The S1 protein of 2019-nCoV shares about 70% identity with that of human SARS-CoVs. |
T47 | 6420-6602 | Sentence | denotes | The highest number of variations of amino acids in the RBD is located in the external subdomain, which is responsible for the direct interaction between virus and host receptor10,18. |
T48 | 6603-6709 | Sentence | denotes | Blocking the initial entry of a virus is proposed as a successful strategy in controlling viral infection. |
T49 | 6710-6903 | Sentence | denotes | Based on SARS vaccine development, most vaccine candidates target the S protein, which induces neutralizing antibody responses and stimulates a protective cellular immunity against SARS-CoVs12. |
T50 | 6904-7078 | Sentence | denotes | Bukreyev et al.19 showed that immunization of African green monkeys with the full-length S protein of SARS-CoV protects monkeys from subsequent homologous SARS-CoV challenge. |
T51 | 7079-7226 | Sentence | denotes | Administration of SARS-CoV RBD proteins can also induce highly potent neutralizing antibodies and long-term protective immunity in animal models20. |
T52 | 7227-7428 | Sentence | denotes | Thus, the generation of antibodies targeting the S1 subunit of SARS-CoV-2 would be an important preventive and treatment strategy that can be tested further in suitable models before clinical trials10. |
T53 | 7429-7562 | Sentence | denotes | Vaccine delivery modality and immunization strategy are important issues to be considered for achieving effective antiviral immunity. |
T54 | 7563-7818 | Sentence | denotes | As a cause of respiratory tract infection and as demonstrated by the findings of SARS-CoV-2 in stools1,21, administration of vaccines by oral or aerosol routes will induce mucosal immune responses and are possible modes of SARS-CoV-2 vaccine immunization. |
T55 | 7819-8101 | Sentence | denotes | A safe DNA vector for preparation of DNA vaccines22, an attenuated virus strain for design of chimeric viral vaccines23, and engineered safe bacteria for production of membrane vesicle-vaccines24 could be explored for vaccine delivery and are worth investigating in the near future. |
T56 | 8102-8187 | Sentence | denotes | We can assume that virus-based vaccines should prove valuable in combatting COVID-19. |
T57 | 8188-8408 | Sentence | denotes | In addition to the entire virus particle-associated inactivated or attenuated viral vaccines, the subunit candidates, such as S1 protein and/or the RBD element of SARS-CoV-2, are also valuable targets for vaccine design. |
T58 | 8409-8701 | Sentence | denotes | Combining subunit vaccines with established or new adjuvants such as alum versus modern adjuvants such as the GSK AS series of adjuvants may represent a faster and safer strategy to move through early clinical development with the caveat that the protective efficacy may not be strong enough. |
T59 | 8702-8859 | Sentence | denotes | As a result, immunizing the subunit vaccines with proper delivery platforms and immunization strategies to enhance the immune responses should be considered. |
T60 | 8860-9020 | Sentence | denotes | We expect researchers who are racing against time will bring a new SARS-CoV-2-based vaccine from gene sequence to clinical testing in approximately 16–20 weeks. |